GLP-1 Medications: What You Need to Know for metabolic Health
A Nutrition Therapy Guide to Preparing Your Body, Optimizing Results, and Supporting Metabolic Health With or Without Medication
Nearly half the world’s population is projected to be overweight or obese by 2030, and GLP-1 receptor agonists, medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have emerged as a powerful clinical tool in response (1). With an estimated 30 million Americans now using these medications, the conversation has expanded far beyond diabetes management (2). As a nutrition therapy practitioner, my role isn’t to tell you whether to use a GLP-1, that’s a conversation for you and your physician. My role is to help you understand the implications of these medications, prepare your body before starting one of these, if this is the route you choose, optimize your response while on it, and/or build the metabolic foundation needed to sustain results if tapering is part of your plan.
Let’s begin the conversation with a brief overview of what a GLP-1 is and how it works.
What GLP-1s Actually Do (And Don’t Do)
GLP-1 (glucagon-like peptide-1) is an incretin hormone your gut naturally produces in response to food. It signals your pancreas to release insulin, slows gastric emptying, suppresses appetite, and even affects the brain’s reward center (3). Your body makes it endogenously, but it only lasts about five minutes in circulation. Compare this with the pharmaceutical versions which are engineered to activate the same receptors, for days rather than minutes (4). That extended action is what makes these medications so potent.
GLP-1 medications can therefore be very effective for weight loss and often improve markers of metabolic health, but they do not automatically address all of the lifestyle, nutritional, behavioral, and psychological factors that may have contributed to weight gain over time. Without intentional nutrition support, some people on GLP-1 therapy may experience changes in digestion and dietary intake that are not optimal for gut health and function. Additionally, these medications have several side effects, so if healthy habits are not established before implementing these, rebound weight gain is common with a loss of precious muscle (5).
Preparing Your Body Before Starting a GLP-1
The best window to build your metabolic foundation is before beginning the medication, while your appetite is still intact and your body is receptive to the habits you are trying to reinforce that poor appetite and other symptoms can make more challenging.
Build muscle now. Research published in Diabetes, Obesity and Metabolism (2024) reported roughly 20–40% of weight lost on GLP-1 therapies may come from lean mass, not just fat (6,7). Having a higher baseline level of muscle mass may help support resting metabolic rate and functional strength during weight loss including with GLP-1 therapy (8). Resistance training 3–5 days per week is the gold standard.
Think protein-forward. International consensus recommendations call for protein intakes above 1.2 g/kg/day, evenly distributed across meals, to preserve lean mass during GLP-1 therapy (9). Because GLP-1 medications reduce appetite and increase satiety, consistently meeting protein needs can become more challenging during treatment. Starting this habit before you begin the medication reinforces its value.
Support your gut. Recent systematic reviews, including publications in Nutrients (2025), suggest that GLP-1 receptor agonist therapy is associated with changes in gut microbiome composition alongside known effects on gastric emptying and intestinal motility (10). These physiological shifts influence digestive function as well as downstream signaling related to inflammation and metabolic regulation.
Within this context, foundational gut-supportive strategies such as adequate fiber intake, hydration, magnesium as needed for regularity, and individualized digestive support, may be beneficial during treatment.
Emerging research also highlights specific microbes, such as Akkermansia muciniphila, which have been associated with improved metabolic markers and may interact with pathways involved in endogenous GLP-1 signaling and insulin sensitivity (11). However, this area remains investigational rather than clinical standard.
This is one reason I place strong emphasis on fiber intake, as it supports microbial diversity, short-chain fatty acid production, and the production of other beneficial metabolites that play a role in gut and metabolic health.
Hydrate intentionally. Fluid intake should be monitored closely because it can be inadequate when on GLP-1 medications (12). Establish a consistent hydration practice now for a proactive strategy for maintaining adequate hydration.
Address insulin resistance. Prediabetes reflects underlying insulin resistance that may progress to type 2 diabetes over time if not addressed. GLP-1 medications can improve insulin sensitivity and glycemic control, (13) while broader assessments, such as thyroid evaluation, metabolic labs, and in some cases gut or hormone testing, may provide additional context for individualized nutrition and lifestyle support.
Phase 2: Optimizing Your Response While on a GLP-1
Once you’re on the medication, your nutrition strategy needs to shift to protect what matters most: lean mass, micronutrient status, and gut integrity.
Protect lean mass. Recent research suggests that combining GLP-1 therapy with regular resistance training and consistent exercise is associated with improved lean mass preservation during weight loss, compared with medication use alone (14). And some individuals were even capable of maintaining or increasing muscle mass tissue while losing fat. This is achievable, but it requires deliberate effort.
Prioritize protein tracking. With appetite suppressed, there’s a documented tendency toward an overall reduction in energy intake, including protein-rich foods. One cross-sectional study of adults using GLP-1 medications found that average protein intake fell well short of the recommended 1.2 to 2.0 grams per kilogram range for people in a calorie deficit (15). Track protein actively. Aim for complete protein sources at every meal. Keep a running list of high-protein, low-volume snack options you can tolerate when appetite is minimal.
Support biliary function. GLP-1 receptor agonist therapy has been associated in clinical studies and meta-analyses with a modestly increased risk of gallbladder-related events, including gallstones, due in part to changes in gallbladder motility and bile composition (16, 17). Maintaining adequate dietary fat intake relative to individual tolerance may help support normal gallbladder stimulation, rather than excessively restricting fat for prolonged periods.
In functional practice, strategies such as supporting digestive capacity through meal composition, hydration, and in some cases targeted use of digestive enzymes or other supplements may be considered to support fat digestion and overall tolerance.
Mind the microbiome. The relationship between GLP-1 and the gut microbiome is bidirectional. The medication alters microbial composition; in turn, the microbiome impacts GLP-1 signaling (11). Fiber and probiotic-rich foods if tolerated, support keystone species involved in metabolic function and may improve satiety signaling alongside the medication.
Track body composition, not just weight. Depending on your budget, a bioimpedance scale or DEXA scan gives a far more meaningful picture than the scale alone. Knowing your muscle-to-fat ratio helps us calibrate nutrition and training interventions in real time. Taken 6 months to a year apart, these can provide a strategy for measuring progress.
Use tracking as an awareness tool, and yes, calories still matter. One of the most powerful awareness tools available right now is learning to track your calories, protein, and fiber using AI tools like ChatGPT. You can describe a meal in plain language, or upload a photo to get an instant macronutrient breakdown, and begin to understand what your food is actually providing, without a food scale, without cumbersome data entry, and without shame. This kind of low-barrier nutritional awareness is genuinely transformative for many clients.
And here’s something worth saying plainly: calorie awareness still has relevance. GLP-1 medications work, in significant part, because they reduce caloric intake, though this is not their only action (3). If calories didn’t matter, these drugs wouldn’t produce the results they do. That’s not a controversial statement.
At the same time, both things can be true. Calories are one lever, and an important one, but they are not the only lever, especially as hormones shift during perimenopause and menopause. Declining estrogen changes how the body stores fat, particularly visceral fat. Cortisol and insulin interactions become more pronounced. Sleep disruption amplifies hunger hormones. A woman in her mid-40s eating the same calories she ate at 35 may still struggle, not because she’s doing something wrong, but because her metabolic terrain has genuinely changed, and she may be experiencing anabolic resistance.
Tracking helps you establish a baseline (targets for calories, protein, fiber, etc.) and guides adjustments that may need to be made. Understanding both the caloric side of the equation and the hormonal, gut, and stress factors that influence how your body uses those calories comprises the full picture. This is why I encourage clients to use AI-assisted food logging not as a diet tool, but as an education tool: a way to build the nutritional literacy that will serve them with or without GLP-1 therapy. In addition to nutrition tracking, AI-assisted tools have the added benefit of easily tracking symptoms in order to quickly recognize symptom patterns, something traditional tracking tools cannot do nearly as efficiently. For many of my clients, calories aren’t even part of their wellness plan and instead they are seeking to understand what might be triggering heartburn, digestive distress, or energy dips.
In general, I aim to find alternatives to tracking for individuals that may have a history of disordered eating. But for those that are open to trying this out, I remind them that its has the potential to be highly illuminating, not intended to be rigid or stress-inducing, and is designed to be temporary.
Address side effects proactively. Nausea, constipation, fatigue, and reduced food joy are common in early treatment (12). These can often be managed through meal timing, food texture modifications, smaller more frequent meals, adequate fiber, magnesium, and walking after eating. However, if symptoms are relentless and debilitating rather than mild and tolerable, that’s important information to bring to your physician. Reduced joy that extends beyond food, into anhedonia or mood changes, may warrant a referral to a therapist or other appropriate health professional.
Preparing to Taper Off If That’s The Goal
Not every client will or should stop GLP-1 therapy. Some will remain on it long-term, and that is a completely valid medical decision to be made with a qualified physician. But for those working toward tapering, preparation is key.
Recent systematic reviews, inclding a 2026 meta-analysis in eClinicalMedicine found that weight gain is common after discontinuation of GLP-1 therapy. On average, a substantial portion of lost weight is regained within the first year, with some individuals maintaining a net reduction below baseline over time (18). A separate 2025 meta-analysis found an average weight gain of about 5.6 kilograms among people with obesity after discontinuation, along with a partial reversal of blood sugar and blood pressure improvements (19). This reflects the return of appetite and energy regulation once the medication is removed.
Emerging evidence suggests that lifestyle support, such as resistance training, dietary consistency, and behavioral coaching may improve weight maintenance after discontinuation of GLP-1 therapy more sustainably (20).
What to consider before you taper:
Lean mass is preserved or actively being built through resistance training
Sustainable, protein-forward eating patterns are established and habitual; preferably above 1.2g/kg of body weight
Stress is being actively managed and sleep is prioritized (both drive appetite dysregulation); this is highly individual and is something a health coach can help address
Underlying inflammation and gut dysfunction have been addressed in order to optimize digestion, absorption, and the microbiome that all play a role in metabolism
Preparing psychologically for appetite to return, without reverting to old patterns is as important as the physical preparation
Tapering is not the finish line. It’s the handoff, from the medication carrying the metabolic load, to the habits and biology you’ve spent time rebuilding.
The Bottom Line
GLP-1 medications are a remarkable clinical tool. But a tool is only as effective as the conditions in which it’s used. Protecting your muscle, healing your gut, tracking your protein, supporting your hormones, and building sustainable habits aren’t things you do after the medication works, they’re supportive alongside the medication, and what carries you forward when it’s potentially no longer in the picture. This is the work of nutrition therapy. And it matters with or without GLP-1 therapy.
Let’s connect. I invite you to book a free 15-minute discovery call to discuss your health goals and explore how a personalized nutrition and lifestyle strategy can help you thrive through perimenopause, menopause, and beyond.
For more information and resources, sign up for the Rebel Roots newsletter.
Carla Abate is Certified in Holistic Nutrition. She specializes nutritional strategies for women and families. She is a level 3 Restorative Wellness Solutions Practitioner, a Certified Nutrition Therapist Master, and a Postpartum Doula. She also holds a Master's degree in Counseling. Carla is dedicated to fostering health and wellness through evidence-based nutrition coaching.
The information provided in this content is for educational purposes only and is not intended to diagnose, treat, or prevent any medical or nutritional conditions. Always consult with a qualified healthcare provider before making any changes to your diet or health regimen.
References
World Obesity Federation. World Obesity Atlas 2023.
KFF Health Tracking Poll, 2024, on public use of GLP-1 agonists for weight loss.
Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. The American Journal of Medicine, 2025.
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. PMC, 2024.
Rebound or Retention: A Meta-Analysis of Weight Regain After the Discontinuation of GLP-1 Receptor Agonists and Other Anti-obesity Drugs. Cureus, 2025.
Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? Circulation, 2024.
Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 2024.
Mozaffarian D, Agarwal M, Aggarwal M, et al. "Nutritional priorities to support GLP-1 therapy for obesity: a joint advisory from the American College of Lifestyle Medicine, the American Society for Nutrition, the Obesity Medicine Association, and The Obesity Society." Obesity. 2025;33(8):1475-1503.
Optimizing GLP-1 therapies for obesity and diabetes management: an international consensus from a global working group. PMC, 2025.
Effects of GLP-1 Analogues and Agonists on the Gut Microbiota: A Systematic Review. Nutrients, 2025.
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. PMC, 2024 (discussion of Akkermansia muciniphila and gut-microbiome metabolic pathways).
Optimizing GLP-1 therapies for obesity and diabetes management. PMC, 2025 (hydration and side effect management recommendations).
GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity. PMC, 2024.
Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series. SAGE Open Medicine, 2025.
Suboptimal protein intake for hypocaloric diet needs while using glucagon-like peptide-1 receptor agonists. Journal of the International Society of Sports Nutrition, 2025.
GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications. PMC, 2025.
Glucagon-like peptide-1 receptor agonist-induced cholecystitis and cholelithiasis: a real-world pharmacovigilance analysis using the FAERS database. PMC, 2025.
Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression. eClinicalMedicine, 2026.
Metabolic rebound after GLP-1 receptor agonist discontinuation: a systematic review and meta-analysis. eClinicalMedicine, 2025.
Weight maintenance after discontinuation of GLP-1 therapies. eClinicalMedicine / ScienceDirect, 2026.